Correlation between the duration of catheterization and the outcome of a trial for patients with acute urine retention due to BPH

A new study demonstrated that patients who have been catheterized due to acute urinary retention secondary to benign prostatic hyperplasia (AUR Secondary to BPH) may experience spontaneous voiding after catheter removal if they are treated with silodosin, regardless of the duration of catheterization. However, side effects tend to increase with longer periods of catheterization. This study’s findings were published in the journal, Urologia.

The study included 260 patients who experienced acute urinary retention secondary to benign prostatic hyperplasia. The patients underwent catheterization and were subsequently allocated at random to receive either 8 mg of silodosin for a period of three days or seven days. After the treatment period, the catheter was removed, and the success of voiding unaided was evaluated.

Out of the 260 men who were treated, 74 men who were on a 3-day silodosin regimen and 88 patients who were on a 7-day silodosin regimen did not require re-catheterization on the day of outcome of trial without catheter (TWOC) (57% and 68% respectively). In the group of participants who underwent the 3-day silodosin regimen, 16.2% experienced complications like acute urinary tract infection, urinary leakage, hematuria, or catheter blockage. On the other hand, in the group that received the 7-day silodosin treatment, 48.5% reported similar issues.

Therefore, silodosin treatment demonstrated positive outcomes in patients who have undergone catheterization as a result of AUR secondary to BPH. Irrespective of the duration of catheterization, these patients can spontaneously void after the removal of the catheter if they are treated with silodosin. It is important to consider that the likelihood of experiencing side effects tends to increase with longer periods of catheterization.